Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025)

Cue Biopharma (CUE) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $678000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 591.84% to $678000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $958000.0 through Dec 2025, up 141.31% year-over-year, with the annual reading at $958000.0 for FY2025, 141.31% up from the prior year.
  • Depreciation & Amortization (CF) hit $678000.0 in Q4 2025 for Cue Biopharma, up from $80000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $678000.0 in Q4 2025 to a low of $80000.0 in Q3 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $204533.1 across 5 years, with a median of $156500.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): crashed 44.33% in 2023 and later soared 591.84% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $309662.0 in 2021, then tumbled by 34.44% to $203000.0 in 2022, then plummeted by 44.33% to $113000.0 in 2023, then decreased by 13.27% to $98000.0 in 2024, then skyrocketed by 591.84% to $678000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CUE at $678000.0 in Q4 2025, $80000.0 in Q3 2025, and $99000.0 in Q2 2025.